199 related articles for article (PubMed ID: 30659301)
1. Clinically occult prostate cancer cases may distort the effect of testosterone replacement therapy on risk of PCa.
Zhang X; Zhong Y; Saad F; Haider K; Haider A; Xu X
World J Urol; 2019 Oct; 37(10):2091-2097. PubMed ID: 30659301
[TBL] [Abstract][Full Text] [Related]
2. Testosterone therapy may reduce prostate cancer risk due to testosterone deficiency at a young age via stabilizing serum testosterone levels.
Zhang X; Zhong Y; Saad F; Haider KS; Haider A; Clendenin AG; Xu X
Aging Male; 2020 Jun; 23(2):112-118. PubMed ID: 30857458
[No Abstract] [Full Text] [Related]
3. Testosterone Replacement Therapy in Hypogonadal Men Following Prostate Cancer Treatment: A Questionnaire-Based Retrospective Study among Urologists in Bavaria, Germany.
Kühn CM; Strasser H; Romming A; Wullich B; Goebell PJ
Urol Int; 2015; 95(2):153-9. PubMed ID: 25677365
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
5. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
6. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
7. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
[TBL] [Abstract][Full Text] [Related]
8. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
[TBL] [Abstract][Full Text] [Related]
9. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
10. Testosterone therapy for men at risk for or with history of prostate cancer.
Morgentaler A
Curr Treat Options Oncol; 2006 Sep; 7(5):363-9. PubMed ID: 16904053
[TBL] [Abstract][Full Text] [Related]
11. [Testosterone replacement therapy for hypogonadism in men with prostate cancer].
Jensen CF; Fode M; Østergren P; Sønksen J
Ugeskr Laeger; 2017 Feb; 179(9):. PubMed ID: 28263152
[TBL] [Abstract][Full Text] [Related]
12. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
13. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
[TBL] [Abstract][Full Text] [Related]
14. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism.
Santella C; Renoux C; Yin H; Yu OHY; Azoulay L
Am J Epidemiol; 2019 Sep; 188(9):1666-1673. PubMed ID: 31145457
[TBL] [Abstract][Full Text] [Related]
15. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
16. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
Leibowitz RL; Dorff TB; Tucker S; Symanowski J; Vogelzang NJ
BJU Int; 2010 May; 105(10):1397-401. PubMed ID: 19912179
[TBL] [Abstract][Full Text] [Related]
17. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
[TBL] [Abstract][Full Text] [Related]
18. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Zhang Y
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):132-43. PubMed ID: 24445948
[TBL] [Abstract][Full Text] [Related]
19. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.
Kaplan AL; Lenis AT; Shah A; Rajfer J; Hu JC
J Sex Med; 2015 Feb; 12(2):374-80. PubMed ID: 25496237
[TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
Pastuszak AW; Pearlman AM; Godoy G; Miles BJ; Lipshultz LI; Khera M
Int J Impot Res; 2013 Jan; 25(1):24-8. PubMed ID: 22971614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]